From: Neuropsychiatric lupus erythematosus in a cohort of Egyptian patients
 | Group I (n = 68) | Group II (n = 66) | p |
---|---|---|---|
ANA | 67 (98.5%) | 63 (95.5%) | 0.362 |
Anti-DNA | 42 (61.8%) | 44 (66.7%) | 0.554 |
C3 Dec | 23 (33.8%) | 35 (53%) | 0.025* |
C4 Dec | 18 (26.5%) | 32 (48.5%) | 0.008* |
ACL IgG | 11 (16.2%) | 5 (7.6%) | 0.125 |
ACL IgM | 11 (16.2%) | 5 (7.6%) | 0.125 |
Lupus anticoagulant | 8 (11.8%) | 1 (1.5%) | FEp = 0.033* |
Anti β 2 GP 1 IgG | 1 (1.5%) | 0 (0%) | FEp = 1.000 |
Anti β 2 GP 1 IgM | 1 (1.5%) | 0 (0%) | FEp = 1.000 |
Anti-Smith | 2 (2.9%) | 2 (3%) | FEp = 1.000 |
Anemia | 49 (72.1%) | 43 (65.2%) | 0.389 |
Leuco-penia | 24 (35.3%) | 20 (30.3%) | 0.539 |
Lympho-penia | 17 (25%) | 16 (24.2%) | 0.919 |
Neutro-penia | 5 (7.4%) | 4 (6.1%) | 1.000 |
Thrombo-cytopenia | 12 (17.6%) | 8 (12.1%) | 0.369 |
Proteinuria | 39 (57.4%) | 41 (62.1%) | 0.574 |